Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01711983
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT01711983
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01711983. Allocation not applicable; no masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2018-11-26 (actual). Results posted on 2020-08-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
- Condition
- Septal Defect, Atrial
- Intervention (Device)
- GORE® CARDIOFORM Septal Occluder
- Lead sponsor
- W.L.Gore & Associates
Record details
- Record id
cardio:ct-nct01711983- Content hash
7fed58190e919c9ef55669e163666dba88a65316c37ba92a4f5f7a44bff87e4e